CT引导经皮微波消融治疗肺癌孤立性肾上腺转移瘤的短期疗效与安全性:多中心回顾性研究
该多中心回顾性研究纳入2010年5月至2014年4月接受CT引导经皮微波消融的31例肺癌单侧肾上腺转移患者,中位随访11.1个月后初始有效率90.3%(28/31),局部肿瘤进展率22.6%(7/31),中位总生存12个月、1年总生存率44.3%,36次消融中主要并发症为高血压危象2次(5.6%);作者认为CT引导经皮微波消融治疗肺癌孤立性肾上腺转移可能相当安全有效。
要点
- 消融后中位随访11.1个月,初始有效率90.3%(28/31),局部肿瘤进展7例(22.6%)。
- 中位总生存12个月,1年总生存率44.3%;中位局部无进展生存9个月,无进展生存率77.4%。
- 36次消融中主要并发症为高血压危象2次(5.6%)。
核心结论
- 作者认为CT引导经皮微波消融治疗肺癌孤立性肾上腺转移可能相当安全有效。
研究设计与样本
- 多中心回顾性研究,纳入2010年5月至2014年4月31例肺癌单侧肾上腺转移接受CT引导经皮微波消融的患者,研究经当地伦理审查委员会批准。
诊断标准与关键数值
- 肿瘤直径1.5至5.4 cm;中位随访11.1个月后初始有效率90.3%(28/31),局部肿瘤进展7/31(22.6%),中位总生存12个月,1年总生存率44.3%,中位局部无进展生存9个月,局部无进展生存率77.4%;36次消融中主要并发症为高血压危象2次(5.6%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To retrospectively evaluate the short-term outcomes and safety of computed tomography (CT)-guided percutaneous microwave ablation (MWA) of solitary adrenal metastasis from lung cancer.
MATERIALS AND METHODS: From May 2010 to April 2014, 31 patients with unilateral adrenal metastasis from lung cancer who were treated with CT-guided percutaneous MWA were enrolled. This study was conducted with approval from local Institutional Review Board. Clinical outcomes and complications of MWA were assessed.
RESULTS: Their tumors ranged from 1.5 to 5.4 cm in diameter. After a median follow-up period of 11.1 months, primary efficacy rate was 90.3% (28/31). Local tumor progression was detected in 7 (22.6%) of 31 cases. Their median overall survival time was 12 months. The 1-year overall survival rate was 44.3%. Median local tumor progression-free survival time was 9 months. Local tumor progression-free survival rate was 77.4%. Of 36 MWA sessions, two (5.6%) had major complications (hypertensive crisis).
CONCLUSION: CT-guided percutaneous MWA may be fairly safe and effective for treating solitary adrenal metastasis from lung cancer.
引用
- Men M, Ye X, Fan W, et al. Short-Term Outcomes and Safety of Computed Tomography-Guided Percutaneous Microwave Ablation of Solitary Adrenal Metastasis from Lung Cancer: A Multi-Center Retrospective Study. Korean J Radiol. 2016. PMID: 27833402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。